BCL2 and non-Hodgkin lymphoma: In this context, it was reported that high Bcl-2 expression predicted sensitivity to ABT-199 in Non-Hodgkin lymphoma cell lines 25 and small cell lung cancer (SCLC) 29, and that SCLC and NSCLC cell lines expressing relatively higher levels of Bcl-2 were more sensitive to the putative Bcl-2 inhibitor, BDA-366 47, 48.